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Development of Lithium-Induced Nephrogenic Diabetes
Insipidus Is Dissociated from Adenylyl Cyclase Activity
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*Department of Physiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and †INSERM
U773 Centre de Recherche Biome´dicale Bichat-Beaujon, Paris France; ‡Universite´ Paris 7 - Denis Diderot, site Bichat,
Paris, France
In antidiuresis, vasopressin (AVP) occupation of V2 receptors in renal collecting ducts activates adenylyl cyclase, resulting in
increased intracellular cAMP levels, which activates protein kinase A (PKA). PKA phosphorylates both the cAMP responsive
element binding protein, which induces aquaporin-2 (AQP2) transcription, and AQP2, which then is translocated to the apical
membrane, allowing urine concentration. Lithium treatment often causes nephrogenic diabetes insipidus (NDI), which
coincides with decreased AQP2 expression and which generally is ascribed to reduced adenylyl cyclase activity. However, the
underlying mechanism by which lithium causes NDI is poorly understood. This study demonstrated that the mouse cortical
collecting duct mpkCCDc14 cells are a good model; the deamino-8 D-arginine vasopressin (dDAVP)-induced endogenous
AQP2 expression and plasma membrane localization was time-dependently reduced by treatment with clinically relevant
lithium concentrations. Lithium did not affect AQP2 stability but decreased its mRNA levels. Surprising, the effect of lithium
was cAMP independent; it did not alter AVP-stimulated cAMP production or PKA-dependent phosphorylation of AQP2 or
cAMP responsive element binding protein. In vivo, kidney tissue of rats with lithium-induced NDI indeed generated less
dDAVP-induced cAMP than that of controls, but this could be due to elevated blood AVP levels in rats with lithium-induced
NDI. Indeed, Brattleboro rats, which lack endogenous AVP, with clamped blood dDAVP levels, showed no difference in
dDAVP-generated cAMP generation between kidneys of rats with lithium-induced NDI and control rats. In conclusion, the
first proper cell model to study lithium-induced NDI was developed, and it was demonstrated that the lithium-induced
downregulation of AQP2 and development of NDI occur independent of adenylyl cyclase activity in vitro and in vivo.
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L ithium is the drug of choice for treating bipolar disor-ders and is prescribed to 1 in 1000 of the population(1,2). It also is currently under consideration as a ther-
apeutic agent for alcoholism, Alzheimer’s disease (3), schizoaf-
fective disorders and AIDS (4), and cluster headaches (5). In 30
to 40% of the patients who take this medication, however,
lithium causes nephrogenic diabetes insipidus (NDI), a disease
in which the antidiuretic effect of the hormone arginine-vaso-
pressin (AVP) is impaired (6), and is therewith the most com-
mon acquired form of NDI. Lithium-induced NDI also exposes
the patient to an increased risk for dehydration-induced lith-
ium toxicity. At present, however, it is still unclear how lithium
affects the AVP-induced water reabsorption in the kidney.
In the normal regulation of water homeostasis, hypovolemia
or hypernatremia causes the release of AVP from the posterior
pituitary into the circulation (for review, see [7]). In the kidney,
AVP binds its vasopressin type 2 receptor (V2R), which is
located in the basolateral membranes of the collecting duct
principal cells. V2R occupation causes activation of adenylyl
cyclase and a subsequent rise in intracellular cAMP levels. The
increased cAMP concentration activates protein kinase A
(PKA), which has at least two targets involved in the regulation
of the aquaporin-2 (AQP2) water channel. First, PKA phosphor-
ylates AQP2 itself, which thereby is translocated from vesicles
to the apical plasma membrane to allow the reabsorption of
water from the pro-urine. Second, cAMP increases AQP2 tran-
scription through phosphorylation of the cAMP responsive
element binding protein (CREB), which then binds and acti-
vates the AQP2 gene promoter (8,9).
Lithium-induced NDI is associated with decreased AQP2
protein and mRNA levels, attenuated apical targeting of AQP2
in rats (10–12), and decreased urine AQP2 excretion in humans
(13). As isolated collecting ducts or kidneys of rats that are
treated long term with lithium show a decreased generation of
cAMP in response to AVP (14–17) and lithium interfered with
the activation of adenylyl cyclase in renal LLC-PK1 cells (18), it
is generally agreed that lithium-induced NDI is due to reduced
AQP2 levels caused by the inhibition of adenylyl cyclases by
lithium (1). However, partly because of the lack of a renal
principal cell line that expresses endogenous AQP2 in response
to AVP, the mechanism by which lithium causes NDI is poorly
understood. Recently, however, a mouse cortical collecting
duct cell line (mpkCCDc14) was generated (19,20), which has
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retained many of the hallmarks of principal cells from native
epithelium, including the expression of endogenous AQP2
when stimulated with physiologic levels of AVP (19–21).
Here, we show that this cell line is an ideal model to study
the mechanism underlying lithium-induced NDI and demon-
strate in detail that in this cell line the administration of ther-
apeutically relevant concentrations of lithium reduces AQP2
expression independent from cAMP generation. Moreover, our
rat studies reveal that the reduced AQP2 levels at early stages
of lithium-induced NDI are also cAMP independent in vivo.
Materials and Methods
Experimental Animals
Male Wistar rats were obtained from the University Animal Facility;
Brattleboro rats were purchased from Harlan Laboratories (Harlan
Sprague Dawley, Indianapolis, IN). Rats that weighed 250 to 350 g were
maintained on a standard rodent diet and had free access to water
before the experiment. For lithium therapy, lithium chloride was added
to the food to give a concentration of 40 mmol/kg dry food for the first
week and 60 mmol/kg thereafter, according to the methods of Marples
et al. (11). All rats that received lithium had access to water ad libitum
and a salt block. Water intake was monitored continuously. Wistar rats
received lithium until development of NDI was established. Mini-
osmotic pumps (ALZET, Model 2001, Durect Co., Cupertino, CA) that
released 1 l/h for 7 d at 37°C were filled with 200 l of 5 ng/l
deamino-8 d-arginine vasopressin (dDAVP) in 0.9% sterile saline and
implanted in the back of the neck of the Brattleboro rats at day 8. These
were replaced at day 15 with new ones. Proper function of the pumps
was revealed by the reduction of urine output and upregulation of
AQP2 expression (see Results). For the last 24 h of the experiment, the
rats were housed in metabolic cages to measure water intake and urine
output and osmolality. All animal treatments were reviewed and ap-
proved by the Animal Experiments Committee of the Radboud Uni-
versity Medical Centre.
Tissue Preparation
Rats were anesthetized by isofluorothane, after which blood was
removed by heart puncture. The rats then were killed by cervical
dislocation, and the kidneys were removed rapidly. The inner medulla,
outer medulla, and cortex were dissected out, and similar-sized tissue
samples were minced using a scalpel. One kidney was used to make
samples for immunoblotting; the other was used for drug treatment
and cAMP analysis.
For immunoblotting, the tissue was homogenized in 1 ml of ice-cold
sucrose dissecting buffer (300 mM sucrose, 25 mM imidazole, 1 mM
EDTA, and protease inhibitors) and cleared from nuclei and unbroken
cells by centrifugation at 4000  g for 15 min and diluted to 0.5 to 1
g/l in Laemmli buffer. For drug treatment and cAMP analysis, the
tissue was suspended in 1 ml modified Krebs-ringer buffer (140 mM
NaCl, 5 mM KCl, 1.2 mM MgSO4, 0.8 mM CaCl2, 10 mM NaOAc, 20
mM Tris, 2 mM NaH2PO4, and 10 mM glucose [pH 7.4]) that contained
0.001% DNase I, prewarmed to 37°C. In this buffer, tissue was incu-
bated for 5 min in 3-isobutyl-1-methylxanthine (IBMX) at 37°C, fol-
lowed by an addition of 1 nM (Wistar rats) or 1 M (Brattleboro rats)
dDAVP for 10 min at 37°C. The tissue was spun down at 800  g and
lysed in 300 l of 0.1 M HCl for 15 min at room temperature. Leftover
tissue was spun down, and the supernatant was used in a colorimetric
competitive immunoassay to measure cAMP (Sigma, St. Louis, MO)
and was analyzed by PAGE and Coomassie brilliant blue staining to
normalize for the amount of lysed tissue.
Blood and Urine Analyses
From the collected blood, serum was prepared by incubation in the
cold, followed by brief centrifugation at 600  g while urine was spun
down to remove sediment. Both serum and urine samples were ana-
lyzed for osmolality and sodium, potassium, lithium, creatinine, and
urea concentrations by standard procedures of the General Clinical
Chemical laboratory the Radboud University Nijmegen Medical Cen-
tre.
Cell Culture
MpkCCD cells (clone 14; passages 26 to 35) were grown as described
previously (19). For growth on semipermeable filters (0.4 m pore size,
Transwell; Corning Costar, Cambridge, MA), exponentially growing
cells were trypsinized and seeded at a density of 1.5  105 cells/cm2;
1-cm2 filters were used for immunoblotting, immunocytochemistry, or
cAMP assays, and 4.7 cm2 filters were used for RNA isolation. In all
experiments, the cells remained in culture for 8 d before being ana-
lyzed. Unless stated otherwise, the cells were treated for the last 96 h
with 1 nM dDAVP to only the basolateral side to induce maximum
AQP2 expression. Lithium (1 or 10 mM) was administered to the apical
side, and 1 mM lithium was administered to the basolateral side.
Cycloheximide (50 M), IBMX (0.25 mM), and ATP (10 M) were
administered to both the apical and the basolateral sides for the indi-
cated time points.
cAMP Assay
cAMP levels were assayed using a direct cAMP enzyme immunoas-
say kit (Sigma). MpkCCD cells were filter seeded and drug treated as
described above. After drug treatments, filters were excised rapidly
from their plastic supports, immersed in 150 l of 0.1 M HCl, and
incubated for 15 min at room temperature. The samples then were
centrifuged at 600  g for 5 min at room temperature; 100 l of the
supernatant was drawn off and used directly in the assay, which was
done according to the manufacturer’s instructions. Data are based on at
least two independent experiments in which triplicates per condition
were taken.
Immunoblotting and Immunocytochemistry
MpkCCD cells from the 1-cm2 filter were lysed in 200 l of Laemmli
buffer, and 15-l samples were analyzed while 5 to 10 g of kidney
material was analyzed. PAGE, blotting, and blocking of the polyvinyli-
dene difluoride membranes were done as described previously (22).
Membranes were incubated overnight with 1:3000-diluted affinity-pu-
rified rabbit AQP2 antibodies (23), 1:250-diluted affinity-purified rabbit
anti-phosphorylated AQP2 antibodies (gift from Dr. S. Nielsen, Aarhus
University, Aarhus, Denmark), 1:100,000-diluted mouse anti-tubulin
antibodies (gift from Dr. Kreis, University of Geneva, Geneva, Switzer-
land), or 1:2000-diluted rabbit anti-CREB and p-CREB antibodies
(Sigma) in TBS-T supplemented with 1% nonfat dried milk. Blots were
incubated for 1 h with 1:5000-diluted goat anti-rabbit IgG or 1:2000 goat
anti-mouse IgG (Sigma) as secondary antibodies coupled to horserad-
ish peroxidase. Proteins were visualized using ECL (Pierce, Rockford,
IL). Immunocytochemistry was done as described previously (24). Data
are based on at least two independent experiments in which triplicates
per condition were taken.
Northern Blotting
Total RNA was isolated from filter-seeded mpkCCD cells using
Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufactur-
er’s protocol. Parallel to a two-fold dilution series of a known RNA
sample for semiquantification, 20 g of RNA of the experimental
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conditions was subjected to a 1% agarose-formaldehyde electrophore-
sis. Subsequent Northern blotting was performed as described previ-
ously (25). The blot was hybridized with full-length [-32P]dCTP-
labeled probes of rat AQP2 or glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), washed, and exposed to high-performance film (Am-
ersham Biosciences, Uppsala, Sweden). Data are based on three inde-
pendent experiments in which duplicates per condition were taken.
Statistical Analyses
Films were scanned using a Bio-Rad (Hercules, CA) 690c densitom-
eter and analyzed using Bio-Rad software. Two-fold dilution series of
protein or mRNA were blotted in parallel to allow semiquantification.
After densitometric analysis of the Western or Northern blots, samples
were corrected for differences in loading by being normalized to the
corresponding amounts of tubulin or GAPDH (in arbitrary units),
respectively. Statistical comparisons were made using the paired t test.
P  0.05 was considered significant.
Results
Lithium Causes Downregulation of AQP2 Expression in
mpkCCD Cells
For determination of the point at which maximal expression
of AQP2 in mpkCCD cells was reached, confluent monolayers
were incubated with 1 nM dDAVP for 0, 24, 48, 72, and 96 h and
lysed. Subsequent immunoblot analysis showed no AQP2 ex-
pression in unstimulated cells, whereas cells that were incu-
bated with dDAVP showed a time-dependent increase in the
expression of unglycosylated (29 kD) and complex glycosylated
(35 to 45 kD) AQP2 (Figure 1A). Immunoblotting for tubulin
revealed that equivalent cell samples were loaded. Semiquan-
tification of the signals (Figure 1B) revealed that AQP2 expres-
sion stabilized after 72 h of dDAVP treatment. For exclusion of
variable AQP2 expression as a result of dDAVP incubation
times, all subsequent experiments were done for a total period
of 96 h of stimulation with dDAVP.
In patients who undergo lithium therapy, 1 mM serum and 1
to 10 mM urinary concentrations of lithium are commonly
observed (1). Therefore, to test whether lithium affects AQP2
expression, were treated mpkCCD cells with or without lithium
for the last 24 or 48 h within the dDAVP treatment. Lithium
was administered in 1 mM concentration to both the basolateral
and the apical compartments or 1 mM basolateral and 10 mM
apical, which is further referred to as 1 or 10 mM lithium,
respectively. Immunoblotting and semiquantification revealed
that lithium treatment resulted in a time- and dose-dependent
reduction in AQP2 expression, with an almost complete down-
regulation of AQP2 with 10 mM lithium for 48 h (Figure 2).
Cytotoxic effects of lithium could be excluded, because the
transepithelial resistance of the monolayer was not affected
(data not shown) and tubulin expression levels were similar for
all samples (Figure 2A). Altogether, these data indicated that
mpkCCD cells are a valuable cell model to investigate the
cellular mechanisms underlying lithium-induced NDI.
Figure 1. Aquaporin-2 (AQP2) expression in mpkCCD cells by
deamino-8 d-arginine vasopressin (dDAVP) is time dependent.
(A) MpkCCD cells were grown to confluence, treated for the
indicated times with 1 nM dDAVP, and subjected to immuno-
blotting for AQP2 or tubulin (indicated). Molecular masses (in
kD) are indicated on the left. Complex-glycosylated (35 to 45
kD) and nonglycosylated (29 kD) forms of AQP2 are detected.
(B) The signals from A were densitometrically quantified and
AQP2 signals were normalized for tubulin. Mean values of
normalized AQP2 expression per time point (indicated) are
given in arbitrary units. Values that are significantly different
(P  0.05) from untreated cells () are indicated by *.
Figure 2. Effects of lithium on dDAVP-stimulated AQP2 expres-
sion in mpkCCD cells. (A) Confluent mpkCCD monolayers
were treated for a total period of 96 h with 1 nM dDAVP in the
absence () or presence of lithium (Li). Cells were incubated
with 1 mM lithium at the basolateral side and 1 or 10 mM
lithium (indicated) at the apical side for the last 24 or 48 h
(indicated). Cells were lysed and immunoblotted for AQP2 or
tubulin. Molecular masses (in kD) are indicated on the left. (B)
Semiquantification of the AQP2 signals and statistical analysis
were done as described in the legend of Figure 1. Mean nor-
malized AQP2 expression values are given as a percentage of
the control () sample.
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Lithium Treatment Alters the Cellular Localization of AQP2
in mpkCCD Cells
To establish the effects of lithium on the cellular redistribu-
tion of AQP2, we subjected lithium-treated mpkCCD cells to
immunocytochemistry and confocal laser scanning microscopy.
Consistent with an earlier study (19) and in agreement with the
need of dDAVP for AQP2 expression, no AQP2 could be de-
tected in untreated cells (Figure 3a), whereas cells that were
stimulated for 96 h with 1 nM dDAVP showed AQP2 expres-
sion at the apical and basolateral membranes (Figure 3b). In
cells that were co-treated with 1 mM lithium for the last 24 h,
plasma membrane staining of AQP2 was decreased, whereas
the intracellular AQP2 staining was increased (Figure 3c). This
effect was even more pronounced with cells that were co-
treated with 1 mM lithium for 48 h or 10 mM lithium for 24 or
48 h (Figure 3, d through f). In the latter situation, AQP2 plasma
membrane staining was virtually absent.
Lithium Does not Alter the Stability of the AQP2 Protein
AQP2 downregulation can be due to increased degradation
or decreased synthesis of AQP2 protein and/or mRNA. To
examine at which level lithium exert its effect, we first studied
its effects on AQP2 protein degradation. dDAVP-stimulated
mpkCCD cells were treated with the protein synthesis inhibitor
cycloheximide and incubated in the absence or presence of 1 or
10 mM lithium for different periods. Immunoblotting for AQP2
revealed that with or without lithium, a reduction in AQP2
expression becomes apparent at 6 h of cycloheximide treat-
ment, which increases at longer incubation times (Figure 4, A
and B). Semiquantification of the signals after normalization for
tubulin revealed that the relative reduction of AQP2 expression
in time was not different between incubations with or without
lithium (Figure 4C). This indicated that lithium does not de-
crease the stability of the AQP2 protein.
Lithium Decreases AQP2 mRNA Expression
To investigate whether lithium affects AQP2 mRNA expres-
sion, total RNA was isolated from mpkCCD cells that were
treated with dDAVP for 0, 24, 48, or 96 h or in the presence of
1 or 10 mM lithium for the last 24 or 48 h. In line with AQP2
protein levels (Figure 1), subsequent Northern blotting re-
vealed that dDAVP treatment increased AQP2 mRNA levels to
a maximal level at 72 h, which was sustained at 96 h (Figure
5A). Lithium treatment seemed to affect the AQP2 mRNA
levels; it resulted in a dose-dependent decrease in AQP2 (Fig-
ure 5A). As the intensity of the GAPDH signals was similar in
all lanes, indicating equal loading, semiquantification of the
Figure 3. Effects of lithium on the cellular distribution of AQP2 in mpkCCD cells. Confluent mpkCCD monolayers were left
untreated (a), treated with 1 nM dDAVP for 96 h (b), or treated with both dDAVP for 96 h and either 1 mM lithium for 24 h (c)
or 48 h (d) or 10 mM lithium for 24 h (e) or 48 h (f), as described in Figure 2. Then, cells were subjected to AQP2 immunocyto-
chemistry and analyzed by confocal laser scanning microscopy.
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signals and normalization for GAPDH confirmed these obser-
vations (Figure 5B).
Lithium Does not Decrease Adenylyl Cyclase Activity in
mpkCCD Cells
In line with the current dogma, the lithium-induced reduc-
tions in AQP2 protein and mRNA levels could be due to
decreased cAMP levels. To investigate this in mpkCCD cells,
we pretreated filter-seeded cells for 24 h with 0, 1, or 10 mM
lithium. During the last 10 min, the phosphodiesterase inhibitor
IBMX was added to inhibit cAMP degradation, and 1 nM
dDAVP was added or not for the last 2 min. Finally, the cells
were lysed and subjected to cAMP assays. In the absence of
lithium, dDAVP caused a four-fold increase in the cAMP con-
centration (Figure 6), indicating activation of adenylyl cyclase
via the V2R signaling cascade. Surprising, however, dDAVP-
stimulated cells that were pretreated with 1 or 10 mM lithium
showed a cAMP accumulation that was even larger than that of
cells that had not been pretreated with lithium. As a negative
control, dDAVP addition in the presence of 10 M ATP, a
known inhibitor of AVP-stimulated cAMP production in the
collecting duct (26), showed a blunted cAMP accumulation
compared with dDAVP alone.
Because raised intracellular cAMP levels activate PKA, which
phosphorylates AQP2 and CREB, analysis of the phosphoryla-
tion state of these proteins represents another indicator of ad-
enylyl cyclase activity. Therefore, confluent mpkCCDmonolay-
ers were treated with 1 or 10 mM lithium for 24 or 48 h, lysed,
and immunoblotted for AQP2, phosphorylated AQP2, CREB,
phosphorylated CREB, and tubulin (Figure 7). Lithium induced
a similar downregulation of phosphorylated AQP2 and total
AQP2, without affecting the levels of tubulin, used as internal
standard (Figure 7A). In the absence of lithium, dDAVP caused
a significant decrease in total CREB without reducing phos-
phorylated CREB levels (P  0.07; Figure 7B). Consistent with
the unaffected AQP2 phosphorylation with lithium, however,
lithium did not reduce CREB phosphorylation when in the
continuous presence of dDAVP (Figure 7, B and C). Altogether,
these data reveal that lithium does not affect V2R-mediated
activation of adenylyl cyclase in mpkCCD cells.
Lithium Does not Affect Adenylyl Cyclase Activity In Vivo
To analyze whether adenylyl cyclase activity is affected in
lithium-induced NDI (i.e., in vivo), we fed three Wistar rats food
that contained lithium to induce NDI, three control rats normal
diet. After 12 d, significant differences in urine volumes and
osmolalities between lithium-fed (106  4 ml/24 h; 146  9
mOsm) and control rats (13  2 ml/24 h; 457  39 mOsm)
indicated that lithium-induced NDI had developed. At this
point, the serum lithium concentration in lithium-fed animals
was 0.71 0.19 mM, whereas that of control animals was below
the detection limit of 0.05 mM. The rats were killed, and their
kidneys were removed immediately. As anticipated, immuno-
blotting of membranes from one kidney inner medulla per rat
for AQP2 and tubulin revealed a marked reduction of AQP2 in
the lithium-treated rats (Figure 8A). The inner medullas of the
contralateral kidneys were used to measure cAMP accumula-
tion after treatment with IBMX or IBMX combined with 1 nM
dDAVP. In the presence of IBMX, dDAVP increased intracel-
lular cAMP levels nearly three-fold in the control rats, whereas
Figure 4. Effects of lithium on AQP2 protein stability in mp-
kCCD cells. (A and B) Confluent mpkCCD monolayers were
treated with 1 nM of dDAVP for 96 h, followed by addition of
50 M cycloheximide (CHX), without or with 10 mM lithium
(Li) for the indicated times. (C) Semiquantification of the
AQP2 signals in A and B was done as described in Figure 2.
Figure 5. Effects of lithium on AQP2 mRNA levels in mpkCCD
cells. (A) Confluent mpkCCD monolayers were treated with 1
nM of dDAVP for the indicated times in the absence or pres-
ence of the indicated concentrations and times of lithium (Li),
as described in Figure 2. Subsequently, total RNA was ex-
tracted and subjected to Northern blotting using AQP2 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probes
(indicated). The approximate lengths of the messengers (in kb)
are indicated on the left. (B) For the 96-h dDAVP treatments
without () or with lithium, AQP2 and GAPDH signals from
three independent experiments were densitometrically quanti-
fied. The AQP2 mRNA levels were normalized for GAPDH.
Data are given and statistically analyzed as described in Figure 2.
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it increased cAMP levels only two-fold in lithium-fed rats (Fig-
ure 8B). Therefore, lithium treatment of rats clearly decreased
dDAVP-stimulated cAMP accumulation in kidneys that were
isolated from these animals.
However, in rats that had lithium-induced NDI, the blood
AVP levels are elevated (27), and, as shown for numerous
receptors in vitro (28), including the V2R (29,30), an increased
receptor occupancy results in their activation, internalization,
and degradation. Therefore, the decreased cAMP accumulation
with renal tissue of lithium-fed rats after dDAVP treatment
might be accounted for by a decreased V2R availability. To test
this hypothesis, we repeated the experiment above with Brattle-
boro rats, which lack endogenous AVP; blood AVP levels were
clamped using implanted minipumps that released continuous
levels of dDAVP. Establishment of a reduced urine volume
(data not shown) before the diuretic effects of lithium treatment
became apparent illustrated proper release of dDAVP from the
minipumps. Eighteen days after the onset of feeding rats with
food with or without lithium, urine volume and osmolalities of
lithium-fed rats (108  18 ml/24 h; 192  36 mOsm) differed
significantly from those of dDAVP-infused control rats (23  9
ml/24 h; 1807  359 mOsm), which indicated that NDI had
developed. Lithium-fed rats had a serum lithium concentration
of 1.20  0.23 mM, whereas that of control rats was undetect-
able. As anticipated, immunoblotting revealed a markedly re-
duced AQP2 expression in the cortex, outer medulla, and inner
medulla of lithium-treated rats compared with controls (Figure
9). The dDAVP-induced cAMP accumulation after 1 M
dDAVP treatment, however, was not different for the cortex
(P  0.21), outer medulla (P  0.36), or inner medulla (P 
0.134) between rats that had lithium-induced NDI and their
controls. This indicated also that in vivo lithium does not affect
cAMP generation by AVP-activated adenylyl cyclases and that
the lithium-induced downregulation of AQP2 occurs indepen-
dent from cAMP.
Discussion
MpkCCD Cells Represent a Proper Model to Study
Lithium-Induced Downregulation of AQP2
The major handicap for deciphering the mechanism by which
lithium induces NDI at the cellular level has been the lack of a
cell line that expresses AQP2 endogenously in response to
physiologic levels of AVP and in which the AQP2 expression is
sensitive to therapeutically relevant lithium levels. We demon-
strated that the mpkCCD cell line fulfills these requirements, as
1- and 10-mM concentrations of lithium cause a time- and
concentration-dependent decrease in AQP2 protein levels (Fig-
ure 2), and the plasma membrane expression of AQP2 was
decreased in response to lithium (Figure 3). These observations
Figure 6. Effects of lithium on dDAVP-stimulated cAMP produc-
tion in mpkCCD cells. MpkCCD monolayers were left untreated
() or treated for 24 h with the indicated concentrations of lithium
(Li), as described in Figure 2. All cells were pretreated with 0.25
mM 3-isobutyl-1-methylxanthine (IBMX) for 10 min. Where indi-
cated (), cells were subsequently stimulated with 1 nM of
dDAVP with or without 10 M ATP for 2 min, in the continuous
presence of lithium where indicated. Cells were lysed and sub-
jected to cAMP measurements. The mean cAMP concentration
([cAMP]  SEM [in pmol/ml]) was determined from three inde-
pendent filters per condition. Significant differences (*P  0.05)
between different conditions are indicated.
Figure 7. Effects of lithium on AQP2/cAMP responsive element
binding protein (CREB) phosphorylation in mpkCCD cells.
Confluent mpkCCD cells were treated for 96 h with 1 nM
dDAVP in the absence () or presence of the indicated concen-
trations and times of lithium (Li), as described in Figure 2.
Then, cells were lysed and immunoblotted for phosphorylated
AQP2 (p-AQP2), AQP2, and tubulin (A) or for CREB and its
phosphorylated form (p-CREB) and tubulin (B). (C) Semiquan-
tification of the CREB and p-CREB signals and statistical anal-
ysis were done as described in the legend of Figure 1. Mean
normalized CREB and p-CREB expression values are given as a
percentage of the control () sample. Molecular masses (in kD)
are indicated on the left.
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are in close agreement with the findings of Marples et al. (11),
who demonstrated the correlation between the onset of lithi-
um-induced NDI and AQP2 downregulation in rats, and the
work from Dousa et al. (31), who showed that lithium affects
microtubule assembly in the renal medulla, thereby inhibiting
the AVP-induced AQP2-mediated antidiuretic effect. As lith-
ium often results in hypercalcemia, which can cause NDI by
itself, the observed downregulation of AQP2 in mpkCCD cells
with lithium under normocalcemic conditions clearly reveals
that lithium also affects AQP2 expression directly.
Lithium Affects AQP2 Gene Transcription in mpkCCD Cells
The lithium-induced reduction in AQP2 expression, as found in
mpkCCD cells, could be due to increased AQP2 protein/mRNA
degradation and/or reduced AQP2 translation/transcription. Us-
ing the protein synthesis inhibitor cycloheximide, no difference in
the level of AQP2 degradation was observed with or without
lithium (Figure 4). As the pulse (chase) labeling assay did not yield
enough product, which is common for polarized cells, we were
not able to determine the effect of lithium on the speed of AQP2
translation. However, lithium caused a strong downregulation of
the AQP2 mRNA levels (Figure 5). As the AQP2 protein levels
usually follow AQP2 mRNA levels, the lithium-induced down-
regulation of AQP2 protein in mpkCCD cells likely originates
from effects on AQP2 transcription and/or mRNA degradation. It
remains to be established which factors mediate the effect of
lithium on AQP2 mRNA levels.
Lithium-Induced Reduction of AQP2 Expression in Lithium-
NDI is cAMP Independent
Our results reveal that both in mpkCCD cells and in vivo, the
lithium-induced downregulation of AQP2 occurs independent
from AVP-induced cAMP levels. In mpkCCD cells, preincuba-
tion with lithium did not affect the cAMP response that was
generated by physiologic levels of AVP (Figure 6). Consistent
with this, whereas lithium reduced dDAVP-induced AQP2 ex-
pression levels, the relative level of the cAMP-dependent AQP2
phosphorylation was not reduced (Figure 7A). In addition,
lithium did not affect CREB expression levels or its level of
phosphorylation (Figure 7, B and C); the latter is cAMP depen-
dent (32). These findings do not corroborate with the observa-
tion that lithium interferes with the activation of adenylyl cy-
clase in LLC-PK1 cells (18). However, LLC-PK1 cells originate
from the renal proximal tubule, whereas lithium-induced NDI
is caused by insufficient functioning of collecting duct principal
cells. The mpkCCD cells that were used in this study are
derived from principal cells, show a reduced AQP2 expression
after lithium treatment, and, therefore, are a better model to
study the mechanism of lithium-induced NDI.
As reported by many others (14–17) and as found in this
study (Figure 8), comparing the cAMP-generating response to
AVP of renal tissue from rats that had lithium-induced NDI
versus controls suggest that lithium reduces AVP-induced
cAMP generation. However, as blood AVP levels are increased
in rats that had lithium-induced NDI (27), the reduced amount
of generated cAMP in lithium-induced NDI renal tissue could
just be due to a reduced number of available V2R, which is a
common negative-feedback response of cells to increased ago-
nist levels (28). Indeed, when the effects of a difference in
endogenous AVP levels were excluded by implanting dDAVP-
filled minipumps into AVP-deficient Brattleboro rats, differ-
ences in dDAVP-induced cAMP generation in the renal cortex,
outer medulla, and inner medulla of rats that had lithium-
induced NDI and control rats were no longer observed,
whereas the AQP2 levels clearly were reduced in the rats that
had lithium-induced NDI (Figure 9). Of note is that the ob-
tained plasma lithium levels were higher in the Brattleboro rats
than in the Wistar rats, which underscores our hypothesis that
the cause by which lithium causes NDI is cAMP independent,
as then one would expect to see a more pronounced difference
in generated cAMP between the lithium and nonlithium groups
of Brattleboro rats than of Wistar rats.
Also, to clamp blood vasopressin levels in the Brattleboro
rats, we used minipumps that released dDAVP, giving a sub-
maximal level of urine-concentrating ability (33). Because the
obtained blood dDAVP levels in these rats likely were in-
Figure 8. Effects of lithium on AQP2 expression and dDAVP-
stimulated cAMP production in rat inner medulla. (A) Three
Wistar rats were fed a normal diet (), and three were fed a diet
that contained lithium (Li). After 12 d, lithium-induced neph-
rogenic diabetes insipidus (NDI) was confirmed, the rats were
killed, and kidneys were removed immediately. Membranes
from one kidney inner medulla per rat were solubilized and
immunoblotted for AQP2 and tubulin (indicated). Molecular
masses (in kD) are indicated on the left. (B) The other kidney
inner medulla of each rat was minced finely and divided into
three portions, which were left untreated, treated with 0.25 mM
IBMX (indicated) for 10 min, or treated with IBMX followed by
stimulated with 1 nM dDAVP for 10 min (IBMX  dDAVP).
The tissue was lysed and subjected to cAMP measurements,
and cAMP values were corrected for protein content. Values
are means  SEM of the corrected cAMP concentration
([cAMP] [in pmol/ml]) from three rats. Significant differences
(*P  0.05) between different groups are indicated.
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creased compared with our Wistar rats and the level of receptor
occupancy by an agonist (here AVP/dDAVP) and, conse-
quently, its removal from the cell surface depends on the con-
centration of the agonist, the cAMP-generating ability of
Brattleboro rat kidney homogenates had to be tested with a
higher dDAVP concentration than used with Wistar rats. Con-
sidering that dDAVP cannot be measured using the standard
assays, 1 M dDAVP seemed to be a well-chosen concentration
because it generated moderate cAMP responses within the
range for sensitive detection of differences (10 to 200 pmol/ml).
One could question whether this higher concentration of
dDAVP would affect our results. Although we cannot exclude
this possibility, this is unlikely for several reasons. First,
dDAVP activates the V2R and V1b receptor at high potency,
but in the rat kidney, only V1a and V2R are expressed (34,35).
Second, 1 M of dDAVP does not seem to activate V1aR,
because treatment of V1aR-expressing rat brain septum tissue
with 1 or even 10 M dDAVP did not result in an increased
inositol-phosphate production (36). Third, the control and lith-
ium-induced NDI Brattleboro groups were similarly infused
with dDAVP. Together, we believe that these and our mpkCCD
cell line data strongly indicate that lithium-induced downregu-
lation of AQP2 and thus lithium-induced NDI occur indepen-
dent from adenylate cyclase activity. Our findings are in line
with the finding that in rats that were treated for only 7 d with
lithium, their lithium-induced polyuria was not interrupted by
low doses of AVP but also not by cAMP (37).
Lithium-Induced NDI Development
On the basis of our data and those of others, lithium-induced
NDI might develop as follows: During the onset of lithium-
induced NDI development (approximately 10 d in rats), collect-
ing duct morphology is not changed, but AQP2 protein levels
are decreased (38). Our data are a model for this early onset, as
the mpkCCD cells were treated with lithium for a maximum of
48 h and did not show a change in the number of cells or
appearance of the intercalated cell marker H-ATPase (data not
shown; see below). Also, our rats were treated for a maximum
of 18 d with lithium and had a normal collecting duct morphol-
ogy (data not shown). Our data indicate that the lithium-in-
duced downregulation of AQP2 in this period is cAMP and
adenylyl cyclase independent and is due to the reduction of
Figure 9. Effects of lithium on AQP2 expression and dDAVP-stimulated cAMP production in kidneys of dDAVP-clamped rats. Six
Brattleboro rats were fed a normal diet (), and six were fed a diet that contained lithium (Li). From day 8 onward, dDAVP-filled
minipumpswere implanted in all rats. On day 18, lithium-inducedNDIwas confirmed, the rats were killed, and kidneys were removed
immediately. Membranes from one kidney inner medulla (A), outer medulla (B), and cortex (C) per rat were solubilized and
immunoblotted for AQP2 and tubulin (indicated). The other kidney inner medulla (A), outer medulla (B), and cortex (C) of each rat was
minced finely, divided into two portions, and analyzed for ability to generate cAMP in response to dDAVP as described in Figure 8,
except that here 1 M dDAVP was used. Values and statistical analysis were done as described in the legend of Figure 8.
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AQP2 mRNA. Presumably as a result of the toxic effect of
lithium on principal cells, chronic lithium therapy (4 wk in
rats) further results in a decreased number of principal cells to
the benefit of intercalated cells (39), which also will contribute
to a reduced dDAVP-induced cAMP generation in kidneys of
rats that had lithium-induced NDI. Recently, cyclo-oxygenase 2
(COX2) expression was suggested to be involved in lithium-
induced NDI (40), but this was debated by others (41). Al-
though our study does not exclude a role of COX-2 in devel-
opment of lithium-induced NDI, the lithium-induced AQP2
downregulation in our mpkCCD cells, which are grown in the
absence of COX2-producing interstitial cells, indicate that
COX2-derived prostaglandins are not necessary for lithium-
induced NDI development.
Although highly debated (42,43), it needs to be noted that
several studies revealed that abnormalities of cAMP signaling
in the brain underlie bipolar disorders (44). Also, lithium treat-
ment for 1 wk reduced receptor-mediated cAMP formation
through inhibition of a Ca2/calmodulin-sensitive adenylyl
cyclase and diminished phosphorylation of the CREB transcrip-
tion factor in brain tissue and cells (2,45,46). As such, our data
that the onset of lithium-induced NDI is cAMP independent
might not be of relevance to the brain.
Conclusion
Our in vitro and in vivo data indicate that we have established
the first appropriate cell model to unravel the mechanism un-
derlying lithium-induced NDI; that lithium-induced down-
regulation is due to diminished AQP2 mRNA levels, likely
through reduced AQP2 gene transcription; and that the onset of
lithium-induced AQP2 degradation and NDI development oc-
curs independent from the activity of principal cell adenylyl
cyclase activity. As such, it resets the scope of the cellular
signaling pathway(s) by which lithium causes AQP2 down-
regulation and NDI development. Several studies in brain re-
port that the positive effect of lithium in bipolar disorders
might be mediated through inhibition of glycogen synthase
kinase 3 and/or phospho-inositol kinases (42,43). It remains to
be established whether these pathways and proteins underlie
lithium-induced NDI. Future studies will focus on the identifi-
cation of the pathways and proteins that are involved in lithi-
um-induced NDI, for which mpkCCD cells seem to be an ideal
model system and may become important pharmacologic tar-
gets to reduce development of NDI in lithium-treated patients
with bipolar disorders.
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